Skip to content

Assessing three day pentamidine for first stage human african trypanosomiasis in Uganda

Assessing three day pentamidine for first stage human african trypanosomiasis in Uganda

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN55042030
Enrollment
440
Registered
2007-12-14
Start date
2007-12-01
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human African Trypanosomiasis (HAT) Infections and Infestations Human African Trypanosomiasis

Interventions

1. Three days pentamidine IM at a dose of 4 mg/kg/day 2. Seven days pentamidine IM at a dose of 4 mg/kg/day Contact details for Principal Investigator:

Sponsors

UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age greater than or equal to 10 years and less than 60 years 2. Trypanosome positive lymph node aspirate or blood 3. Consenting patient 4. Alternative diagnoses excluded by appropriate clinical and laboratory investigations

Exclusion criteria

Exclusion criteria: 1. Abnormal Cerebrospinal Fluid (CSF): 1.1. CSF White Blood Cell [WBC] count greater than 5 WBC/µl 1.2. Presence of trypanosomes 1.3. Haemorrhagic CSF 2. Pregnant 3. Previous HAT treatment 4. Known allergy or reaction to pentamidine 5. Diabetes mellitus 6. Severe difficulty expected with follow-up. Follow-up is difficult for all patients; only if it appears very probable that a patient will not be able to present for follow-up examinations until 18 months post-treatment should he/she be excluded (e.g. Sudanese refugees who have enrolled in the ongoing voluntary repatriation programme) 7. Patients with severe chronic conditions for whom the chance of survival until the end of the 18 months follow-up period is doubtful (e.g. clinical Human Immunodeficiency Virus [HIV]/Acquired Immune Deficiency Syndrome [AIDS] stage IV and Tuberculosis)

Design outcomes

Primary

MeasureTime frame
Proportion of cases with favourable evolution at 6 months post-treatment, based on laboratory results.

Secondary

MeasureTime frame
1. Proportion of cases with favourable evolution at the end of treatment assessment (day 10), 3 and 12 months post-treatment, based on laboratory results 2. Cure rate at 18 months post-treatment, based on laboratory results 3. Frequency and severity of adverse events

Countries

Uganda

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026